Get the Stockscreener App
9.13
0.98%
-0.09
Cervomed Inc stock is traded at $9.13, with a volume of 178.42K.
It is down -0.98% in the last 24 hours and up +10.67% over the past month.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
See More
Previous Close:
$9.22
Open:
$9.12
24h Volume:
178.42K
Relative Volume:
0.51
Market Cap:
$84.48M
Revenue:
-
Net Income/Loss:
$-6.42M
P/E Ratio:
-1.63
EPS:
-5.6013
Net Cash Flow:
$-7.45M
1W Performance:
-9.78%
1M Performance:
+10.67%
6M Performance:
+300.44%
1Y Performance:
-41.85%
1-Day Range:
$8.91
$9.50
1-Week Range:
$8.76
$11.25
52-Week Range:
$1.80
$20.63
Cervomed Inc Stock (CRVO) Company Profile
Name
Cervomed Inc
Sector
Industry
Phone
(617) 744-4400
Address
20 PARK PLAZA, BOSTON
Compare CRVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
9.13 | 85.55M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Dec-17-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-11-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-11-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-10-24 | Downgrade | D. Boral Capital | Buy → Hold |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Dec-05-24 | Initiated | H.C. Wainwright | Buy |
| Sep-18-24 | Initiated | Chardan Capital Markets | Buy |
| Jul-26-24 | Initiated | Morgan Stanley | Overweight |
| Feb-15-24 | Initiated | Canaccord Genuity | Buy |
| Nov-17-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-21-18 | Initiated | H.C. Wainwright | Buy |
View All
Cervomed Inc Stock (CRVO) Latest News
CervoMed Reports Promising Trial Results and Financial Update - MSN
D. Boral Capital Maintains CervoMed(CRVO.US) With Buy Rating, Raises Target Price to $31 - 富途牛牛
CervoMed price target raised to $31 from $15 at D. Boral Capital - TipRanks
CervoMed: D. Boral Capital Raises Buy Rating, PT to $31 from $15 - AInvest
Can machine learning forecast CervoMed Inc. recoveryWeekly Trend Report & Smart Swing Trading Alerts - Newser
CervoMed Inc. stock trend forecastJuly 2025 Outlook & Low Risk High Win Rate Picks - Newser
How to build a dashboard for CervoMed Inc. stockProduct Launch & Weekly High Conviction Ideas - Newser
CervoMed Inc. stock chart pattern explainedWeekly Earnings Recap & Real-Time Stock Price Movement Reports - Newser
How Resilient Is CervoMed Inc. Stock During Economic DownturnsInsider Selling & Fast Gain Swing Alerts - Newser
Applying sector rotation models to CervoMed Inc.Insider Selling & Free Verified High Yield Trade Plans - Newser
What MACD signals say about CervoMed Inc.2025 Price Action Summary & Step-by-Step Swing Trade Plans - Newser
Best data tools to analyze CervoMed Inc. stockInflation Watch & Consistent Return Investment Signals - Newser
Leading vs lagging indicators on CervoMed Inc. performanceMarket Performance Report & Daily Market Momentum Tracking - Newser
CervoMed’s Promising Developments and Financial Stability Drive Buy Rating with $20 Price Target - TipRanks
Is CervoMed Inc. a strong growth stockQuarterly Risk Review & Consistent Profit Alerts - thegnnews.com
FY2025 EPS Estimates for CervoMed Boosted by Chardan Capital - Defense World
Roth Capital Estimates CervoMed’s Q3 Earnings (NASDAQ:CRVO) - Defense World
Is CervoMed Inc. a turnaround storyMarket Trend Summary & Real-Time Volume Analysis - newsimpact.co.kr
Fibonacci Retracement Aligns with Support in CervoMed Inc.2025 Biggest Moves & Growth Focused Investment Plans - beatles.ru
CervoMed (NASDAQ:CRVO) Stock Price Expected to Rise, D. Boral Capital Analyst Says - Defense World
Chardan Capital Reiterates Buy Rating for CervoMed (NASDAQ:CRVO) - Defense World
Can CervoMed Inc. hit a new high this monthYield Curve Outlook and Long-Term Implication Summary - Newser
CervoMed: Roth Capital Downgrades Buy to $16 from $20 PT. - AInvest
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $27 - 富途牛牛
CervoMed Reports Second Quarter 2025 Financial Results and Provi - GuruFocus
CervoMed reports Q2 EPS (70c), consensus (50c) - TipRanks
CervoMed Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - TradingView
Breakthrough: CervoMed's Dementia Drug Cuts Disease Progression Risk by 54% in Phase 2b Trial - Stock Titan
CervoMed stock price target raised to $15 from $10 at D. Boral Capital By Investing.com - Investing.com South Africa
CervoMed stock price target raised to $15 from $10 at D. Boral Capital - Investing.com Canada
How CervoMed Inc. stock performs during market volatilityTrend Confirmation Scanner with Entry Focus - Newser
CervoMed Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
CervoMed 2025 Q2 Earnings Deepening Losses Amid Revenue Decline - AInvest
12,028 Shares in CervoMed Inc. (NASDAQ:CRVO) Purchased by Bank of New York Mellon Corp - Defense World
Cervomed Inc. shares fall 1.69% intraday after corporate presentation on Neflamapimod in dementia with Lewy bodies. - AInvest
How to track smart money flows in CervoMed Inc.Free Buy Low Sell High Stock Watch - Newser
CervoMed Shares Business and Financial Updates Online - TipRanks
CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
CervoMed Reveals Neurologic Treatment Progress: Key Presentation at Major Growth Conference Next Week - Stock Titan
Is CervoMed Inc. stock overvalued or undervaluedDouble or triple returns - Jammu Links News
What is the risk reward ratio of investing in CervoMed Inc. stockUnmatched profit potential - Jammu Links News
What analysts say about CervoMed Inc. stockAchieve breakthrough financial results - Jammu Links News
When is CervoMed Inc. stock expected to show significant growthBreakthrough investment results - Jammu Links News
What are CervoMed Inc. company’s key revenue driversMaximize portfolio value with smart investment plans - Jammu Links News
What is CervoMed Inc. company’s growth strategyFree Stock Market Forecast Reports - Jammu Links News
Should I hold or sell CervoMed Inc. stock in 2025Amplify your gains with low-risk picks - Jammu Links News
What drives CervoMed Inc. stock priceExponential wealth increase - Jammu Links News
Is CervoMed Inc. a growth stock or a value stockHigh-yield trading alerts - Jammu Links News
Is it the right time to buy CervoMed Inc. stockBreakout stock performance - jammulinksnews.com
CervoMed Inc. (NASDAQ:CRVO) Surges 53%; Retail Investors Who Own 48% Shares Profited Along With Insiders - 富途牛牛
CervoMed Shares Surge After Promising Dementia Drug Trial Results - MSN
Cervomed Inc Stock (CRVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cervomed Inc Stock (CRVO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ELDER WILLIAM ROBERT | CFO & GC |
Aug 27 '24 |
Buy |
18.16 |
1,000 |
18,160 |
1,267 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):